Flushes In Women Research Articles

Phase 2 data on a new treatment for hot flushes in women with breast cancer

Bothersome vasomotor symptoms (ie, hot flashes or flushes and night sweats) are common after breast cancer, sometimes aggravated by chemotherapy-induced premature menopause or adjuvant endocrine treatments. Consequently, there is a long history of clinical trials testing a variety of centrally acting agents, including selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, and others,1,2 to manage vasomotor symptoms when menopausal oestrogen therapy (transdermal or oral oestrogens) is contraindicated.

Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

The meta-analysis presented in this article covered the efficacy of red clover isoflavones in relieving hot flushes and menopausal symptoms in perimenopausal and postmenopausal women. Studies were identified by MEDLINE (PubMed), Embase, and the Cochrane Library searches. The quality of the studies was evaluated according to Cochrane criteria. A meta-analysis of eight trials (ten comparisons) demonstrated a statistically significant reduction in the daily incidence of hot flushes in women receiving red clover compared to those receiving placebo: weighted mean difference (WMD—weighted mean difference) −1.73 hot flushes per day, 95% CI (confidence interval) −3.28 to −0.18; p = 0.0292. Due to 87.34% homogeneity, the performed analysis showed substantive difference in comparisons of postmenopausal women with ≥5 hot flushes per day, when the follow-up period was 12 weeks, with an isoflavone dose of ≥80 mg/day, and when the formulations contained a higher proportion of biochanin A. The meta-analysis of included studies assessing the effect of red clover isoflavone extract on menopausal symptoms showed a statistically moderate relationship with the reduction in the daily frequency of hot flushes. However, further well-designed studies are required to confirm the present findings and to finally determine the effects of red clover on the relief of flushing episodes.

22 - Association of genetic variations for prediction of hot flushes in women taking tamoxifen for breast cancer prevention

22 - Association of genetic variations for prediction of hot flushes in women taking tamoxifen for breast cancer prevention

Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial.

ObjectiveTroublesome hot flushes and night sweats (HFNS) are experienced by many women after treatment for breast cancer, impacting significantly on sleep and quality of life. Cognitive behavioural therapy (CBT) is known to be effective for the alleviation of HFNS. However, it is not known if it can effectively be delivered by specialist nurses. We investigated whether group CBT, delivered by breast care nurses (BCNs), can reduce the impact of HFNS.MethodsWe recruited women with primary breast cancer following primary treatment with seven or more HFNS/week (including 4/10 or above on the HFNS problem rating scale), from six UK hospitals to an open, randomised, phase 3 effectiveness trial. Participants were randomised to Group CBT or usual care (UC). The primary endpoint was HFNS problem rating at 26 weeks after randomisation. Secondary outcomes included sleep, depression, anxiety and quality of life.ResultsBetween 2017 and 2018, 130 participants were recruited (CBT:63, control:67). We found a 46% (6.9‐3.7) reduction in the mean HFNS problem rating score from randomisation to 26 weeks in the CBT arm and a 15% (6.5‐5.5) reduction in the UC arm (adjusted mean difference −1.96, CI −3.68 to −0.23, P = .039). Secondary outcomes, including frequency of HFNS, sleep, anxiety and depression all improved significantly.ConclusionOur results suggest that specialist nurses can be trained to deliver CBT effectively to alleviate troublesome menopausal hot flushes in women following breast cancer in the NHS setting.

P013: MENOS4 trial: Nurses can be trained to effectively deliver CBT for menopausal hot flushes in women with breast cancer to reduce hot flush bother and improve quality of life

Introduction: Hot flushes and night sweats (HFNS) are a common problem in women after breast cancer, often with a significant impact on daily life. Cognitive Behavioural Therapy (CBT) is effective for the alleviation of HFNS, but not widely available. This study assessed whether breast care nurses can be trained to effectively deliver a CBT intervention to alleviate hot flushes in women with breast cancer in the NHS setting.

Oral investigational drugs currently in phase I or phase II for the amelioration of menopausal symptoms

ABSTRACTIntroduction: Menopausal symptoms have a substantial effect on the quality of life of many women; hence, investigations for the amelioration of menopausal symptoms continue to be necessary. The two main approaches to the amelioration of symptoms are hormone therapy (HT) and non-hormonal therapy.Areas covered: This review provides a background for understanding the types of menopausal symptoms and their underlying physiology. The early clinical development of natural estrogen (estetrol, E4), neurokinin 3 receptor (NK3R) antagonists, and other non-hormonal therapies are covered. The status and outcome of these novel treatment modalities are also discussed.Expert opinion: The recent observation in the Women’s Health Initiative (WHI) trials that HT was not associated in the long-term with all-cause mortality, brings renewed interest in the development of new treatment modalities in postmenopausal women. Estetrol (E4), a native estrogen with selective action in tissues, is a potential next-generation HT with improved cardiovascular and breast safety. NK3R antagonists may become an interesting new modality for the amelioration of hot flushes in women with contraindications to estrogens.Trial registration: ClinicalTrials.gov identifier: NCT00163033.Trial registration: ClinicalTrials.gov identifier: NCT02834312.Trial registration: ClinicalTrials.gov identifier: NCT03192176.Trial registration: ClinicalTrials.gov identifier: NCT02865538.Trial registration: ClinicalTrials.gov identifier: NCT03596762.Trial registration: ClinicalTrials.gov identifier: NCT02668185.Trial registration: ClinicalTrials.gov identifier: NCT02803268.Trial registration: ClinicalTrials.gov identifier: NCT03291067.Trial registration: ClinicalTrials.gov identifier: NCT03541200.Trial registration: ClinicalTrials.gov identifier: NCT03285672.Trial registration: ClinicalTrials.gov identifier: NCT03518138.

P14.02: Assessing the pregnancy rate following Lipiodol flush in women with subfertility

P14.02: Assessing the pregnancy rate following Lipiodol flush in women with subfertility

MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: Study Protocol

BackgroundWomen who have been treated for breast cancer may identify vasomotor symptoms, such as hot flushes and night sweats (HFNS), as a serious problem. HFNS are unpleasant to experience and can have a significant impact on daily life, potentially leading to reduced adherence to life saving adjuvant hormonal therapy. It is known that Cognitive Behavioural Therapy (CBT) is effective for the alleviation of hot flushes in both well women and women who have had breast cancer. Most women with breast cancer will see a breast care nurse and there is evidence that nurses can be trained to deliver psychological treatments to a satisfactory level, whilst also maintaining treatment fidelity. The research team will assess whether breast care nurses can effectively deliver a CBT intervention to alleviate hot flushes in women with breast cancer.MethodsThis study is a multi-centre phase III individually randomised controlled trial of group CBT versus usual care to reduce the impact of hot flushes in women with breast cancer. 120–160 women with primary breast cancer experiencing seven or more problematic HFNS a week will be randomised to receive either treatment as usual (TAU) or participation in the group CBT intervention plus TAU (CBT Group).A process evaluation using May’s Normalisation Process Theory will be conducted, as well as practical and organisational issues relating to the implementation of the intervention. Fidelity of implementation of the intervention will be conducted by expert assessment. The cost effectiveness of the intervention will also be assessed.DiscussionThere is a need for studies that enable effective interventions to be implemented in practice. There is good evidence that CBT is helpful for women with breast cancer who experience HFNS, yet it is not widely available. It is not yet known whether the intervention can be effectively delivered by breast care nurses or implemented in practice. This study will provide information on both whether the intervention can effectively help women with hot flushes and whether and how it can be translated into routine clinical practice.Trial registrationISRCTN 12824632. Registered 25–01-2017.

Pharmacological issues in cancer patients

IntroductionDepression and anxiety are the main causes of psychiatric disorder in cancer patients, associated with a decreased tolerance and adherence to cancer treatment, longer hospital stays, decreased quality of life and possibly influence prognosis and mortality.ObjectivesThis review will address psychopharmacological options in cancer patients, side effects and possible drug interactions between psychotropic drugs and chemotherapy, either by toxicity, to which these patients are more sensitive, or a reduction in efficacy in anti-tumor treatment.MethodsNon systematic literature review through the Medline and clinical key databases, with time constraints.ResultsSelective Serotonin Reuptake Inhibitors are the first line treatment for depression, because of their tolerability and safety profile. Venlafaxine is the safer choice for the treatment of depression and hot flushes in women with breast cancer undergoing chemotherapy with tamoxifen. Tricyclic antidepressants are used in patients with neuropathic pain, due to its analgesic properties. Haloperidol is the safest antipsychotic, with less drug interactions and lower metabolic risk. Benzodiazepines are used in anxiety states for short periods. Psychostimulants are an option in patients with depression and life expectancy of less than one month. Mood stabilizers are recommended to treat mania, commonly induced by corticosteroids.ConclusionsTreatment of psychiatric disease in cancer patients leads to an increased adherence to anti-tumoral treatment and improves quality of life. Regardless of the cancer stage there is indication to start treatment. We must, however, take into account possible side effects and drug interactions between psychotropic drugs and chemotherapy, through toxicity or diminished efficacy, when combined with anti-tumoral treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Limited clinical evidence to support the use of herbal remedies to alleviate endocrine-therapy-induced hot flushes in women with breast cancer

Focus on Alternative and Complementary TherapiesVolume 21, Issue 3-4 p. 162-163 Summaries and Commentaries Limited clinical evidence to support the use of herbal remedies to alleviate endocrine-therapy-induced hot flushes in women with breast cancer Y Clement, Y Clement yuriclem@yahoo.com Pharmacology Unit, Faculty of Medical Sciences, The University of the West Indies, St Augustine, Trinidad and TobagoSearch for more papers by this author Y Clement, Y Clement yuriclem@yahoo.com Pharmacology Unit, Faculty of Medical Sciences, The University of the West Indies, St Augustine, Trinidad and TobagoSearch for more papers by this author First published: 24 April 2017 https://doi.org/10.1111/fct.12272Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume21, Issue3-4December 2016Pages 162-163 RelatedInformation

Non-hormonal interventions for hot flushes in women with a history of breast cancer

BACKGROUND Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain. OBJECTIVE To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer. METHODS Search methods: We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL (The Cochrane Library), Medline, Embase, Lilacs, CINAHL, PsycINFO (August 2008) and WHO ICTRP Search Portal. We handsearched reference lists of reviews and included articles, reviewed conference proceedings and contacted experts. Selection criteria: Randomized controlled trials (RCTs) comparing non-hormonal therapies with placebo or no therapy for reducing hot flushes in women with a history of breast cancer. Data collection and analysis: Two authors independently selected potentially relevant studies, decided upon their inclusion and extracted data on participant characteristics, interventions, outcomes and the risk of bias of included studies. MAIN RESULTS Sixteen RCTs met our inclusion criteria. We included six studies on selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitors, two on clonidine, one on gabapentin, two each on relaxation therapy and homeopathy, and one each on vitamin E, magnetic devices and acupuncture. The risk of bias of most studies was rated as low or moderate. Data on continuous outcomes were presented inconsistently among studies, which precluded the possibility of pooling the results. Three pharmacological treatments (SSRIs and SNRIs, clonidine and gabapentin) reduced the number and severity of hot flushes. One study assessing vitamin E did not show any beneficial effect. One of two studies on relaxation therapy showed a significant benefit. None of the other non-pharmacological therapies had a significant benefit. Side-effects were inconsistently reported. AUTHORS' CONCLUSIONS Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

Background:Several studies have reported discordant results regarding the impact of the CYP2D6 phenotype on both the effectiveness and the degree of endocrine symptoms associated with tamoxifen. Other studies have suggested that menopausal symptoms may be a predictive factor to tamoxifen response.Methods:We investigated the relationship between the CYP2D6-predicted phenotype and tamoxifen response in a nested case–control study among women from the International Breast cancer Intervention Study (IBIS-I), which evaluated tamoxifen in the preventive setting.Results:In this retrospective analysis of the tamoxifen-treated women in the IBIS-I study, 9 women (16.6%) who developed oestrogen receptor-positive invasive breast cancer had a 2D6 poor or intermediate metaboliser phenotype compared with 45 (20.6%) controls. Adjusted matched logistic regression revealed no significant difference between cases and controls for extensive vs intermediate metaboliser phenotype (OR=0.81 (0.30–2.23), P=0.7) or extensive vs poor metaboliser phenotype (OR=1.02 (0.31–3.32), P=0.9). Controls in the tamoxifen group with a poor metaboliser phenotype developed nonsignificantly fewer hot flushes compared with those with an extensive metaboliser phenotype (OR=0.40 (0.12–1.31)), but those with the intermediate phenotype developed nonsignificantly more hot flushes (OR=1.38 (0.58–3.29)) in an unadjusted analysis.Conclusion:Data from the preventive IBIS-I study did not support an association between the CYP2D6 phenotype and breast cancer outcome or the development of endocrine symptoms in tamoxifen-treated women.

A randomised controlled trial of a cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN): trial protocol.

BackgroundThis randomised controlled trial (RCT) aims to evaluate the effectiveness of a guided self-help cognitive behavioural intervention to alleviate problematic hot flushes (HF) and night sweats (NS) in men who are undergoing prostate cancer treatment. The trial and the self-help materials have been adapted from a previous RCT, which showed that a cognitive behavioural intervention reduced the self-reported problem-rating of hot flushes in women with menopausal symptoms, and in women undergoing breast cancer treatment. We hypothesize that guided self-help will be more effective than usual care in reducing HF/NS problem-rating at post treatment assessment.Methods/DesignSeventy men who are undergoing treatment for prostate cancer and who have been experiencing more than ten HF/NS weekly for over a month are recruited into the trial from urology clinics in London. They are randomly allocated to either a four-week self-help cognitive behavioural therapy (CBT) treatment or to their usual care (control group). The treatment includes information and discussion about hot flushes and night sweats in the context of prostate cancer, monitoring and modifying precipitants, relaxation and paced respiration, stress management, cognitive therapy for unhelpful thoughts and beliefs, managing sleep and night sweats, and advice on maintaining these changes.Prior to randomisation, men attend a clinical interview, undergo 24-48-hour sternal skin conductance monitoring, and complete pre-treatment questionnaires (e.g., problem-rating and frequency of hot flushes and night sweats; quality of life; mood; hot flush beliefs and behaviours). Post-treatment measures (sternal skin conductance and the above questionnaires) are collected four-six weeks later, and again at a six-month follow-up.DiscussionMANCAN is the first randomised controlled trial of cognitive behavioural therapy for HF/NS for men that measures both self-reported and physiologically indexed symptoms. The results will inform future clinical practice by evaluating an evidence-based, non-medical treatment, which can be delivered by trained health professionals.Trial registrationUK Clinical Research Network UKCRN10904.

Hot flushes in healthy aging men differ from those in men with prostate cancer and in menopausal women

Calcitonin gene-related peptide (CGRP) seems to be involved in hot flushes in women and in castrated men. Therefore, we studied whether the plasma concentrations of CGRP changed during flushes in a group of healthy aging men. Twelve men (49–71 years) with no history of current or former prostate cancer or hormonal treatment reporting ≥20 flushes/week were investigated. Blood samples were drawn during and between flushes for analysis of CGRP and also androgen concentrations, that is, testosterone and bioavailable testosterone were analysed. Skin temperature and skin conductance were monitored. Thirty-five flushes were reported by 10 men. The plasma concentrations of CGRP did not increase during flushes. No significant change in skin temperature or conductance was found. CGRP is probably not involved in the mechanisms of flushes in healthy aging men. Therefore, flushes in aging healthy men seem to be different from flushes in men and women deprived of sex steroids where CGRP increases during flushes.

A phase II pilot of St. John’s wort for the treatment of hot flushes in women with a history of breast cancer.

e19685 Background: Effective treatments for hot flush reduction among post-menopausal breast cancer survivors are sparse. We conducted a pilot study of the use of St. John’s Wort in reducing the frequency and severity of hot flushes over a 4 week period. Methods: Participants were recruited from the CCOP Research Base of the Comprehensive Cancer Center of Wake Forest University. Women were aged >/= 18 years, two or more years from active treatment for non-metastatic breast cancer, and with a minimum of 3 hot flushes per day or 21 per week. Women were ineligible if they were taking an aromatase inhibitor, receiving cytotoxic chemotherapy, or on medication for the management of hot flushes (e.g., estrogen, antidepressants). Participants completed a 1 week pill run-in to determine any drug intolerance and adherence concerns, and then took three 300 mg St. John’s Wort capsules daily for 4 weeks. Participants completed hot flush diaries during active treatment (weeks 1-4), and for two weeks post-treatment (weeks 5-6) to assess hot flush frequency and severity. In addition, women completed quality of life assessments (SF-12 and Profile of Mood States [POMS]) at baseline, 2, 4 and 6 weeks. Results: 9 women were recruited and all were 100% compliant in taking the study pills and completing forms. Recruitment was hampered by the FDA requirement that no participants could be on aromatase inhibitors while on study. All participants were Caucasian with a mean age of 53 years (range: 48-70). No adverse events were reported. Analyses indicated that St. John’s Wort was not effective in reducing either the frequency (p=0.98) or severity (p=0.29) of hot flushes among the study participants. Quality of life, as assessed by the SF-12 (i.e., PCS [p=0.80]; MCS [p=0.29]), and the POMS (p=0.08), was also not improved by the use of St. John’s Wort. Conclusions: St. John’s Wort was not effective in reducing the number and severity of hot flushes in this pilot, or in improving quality of life.

Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term

Commentary on: G Rada, D Capurro, T Pantoja, et al.. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010;9:CD004923.

Omission of Final Page Number of Article Citation in: An Intensive Behavioral Weight Loss Intervention and Hot Flushes in Women

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue

Non-hormonal interventions for hot flushes in women with a history of breast cancer

Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain. To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer. We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, CINAHL, PsycINFO (August 2008) and WHO ICTRP Search Portal. We handsearched reference lists of reviews and included articles, reviewed conference proceedings and contacted experts. Randomized controlled trials (RCTs) comparing non-hormonal therapies with placebo or no therapy for reducing hot flushes in women with a history of breast cancer. Two authors independently selected potentially relevant studies, decided upon their inclusion and extracted data on participant characteristics, interventions, outcomes and the risk of bias of included studies. Sixteen RCTs met our inclusion criteria. We included six studies on selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitors, two on clonidine, one on gabapentin, two each on relaxation therapy and homeopathy, and one each on vitamin E, magnetic devices and acupuncture. The risk of bias of most studies was rated as low or moderate. Data on continuous outcomes were presented inconsistently among studies, which precluded the possibility of pooling the results. Three pharmacological treatments (SSRIs and SNRIs, clonidine and gabapentin) reduced the number and severity of hot flushes. One study assessing vitamin E did not show any beneficial effect. One of two studies on relaxation therapy showed a significant benefit. None of the other non-pharmacological therapies had a significant benefit. Side-effects were inconsistently reported. Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.

10th Annual Congress of the German Association of Clinical Pharmacology

10th Annual Congress of the German Association of Clinical Pharmacology

Long term follow up of acupuncture and hormone therapy on hot flushes and well-being in women with breast cancer – a prospective, randomized multi centre trial.

Abstract Abstract #2162 Background: There are few treatments for hot flushes in women with a history of breastcancer. We wanted to evaluate effects of electro-acupuncture (EA) and hormone therapy (HT) on vasomotor symptoms and wellbeing in these women.
 Material and Methods: 45 women were randomized to EA (n=27) for 12 weeks or HT (n=18) for 24 months. The number of and distress by hot flushes were registered before, during and up to 24 months after start of treatment (ast). Kupperman's Index (KI), Women's Health Questionnaire (WHQ) and Psychological and General Wellbeing Index (PGWB) were recorded before, after 3 months of treatment, and at 6, 9, 12, 18 and 24 months ast. PGWB includes 22 questions, total score 110. WHQ has 35 questions and scores 0-1.Wilcoxon signed rank test was used for changes over time within groups. Results: 19 women completed 12 weeks of EA, and the median number of hot flushes/24h decreased from 9.6 (interquartile range (IQR)6.6-9.9) at baseline to 4.3(IQR 1.0-7.1) at 12 weeks of treatment (p<0.001). At 12 months ast, 14 women with only the initial 12 weeks of EA had a median number of flushes/24 h of 4.9(IQR1.8-7.3), and at 24 months seven women with no other treatment than EA had 2.1(IQR1.6-2.8) flushes/24h. Another five women had decreased flushes by having additional EA. KI went from a median score of 24(IQR19-29;n=26) to 12(IQR 9-17;n=19) after 12 weeks of treatment (p< 0.001), and was 13(IQR 10-17;n=14) at 12 months ast (p=0.002). Median PGWB changed from 78(IQR 53-89;n=26) at baseline to 79(IQR 68-93;n=19) after 12 weeks of treatment (p=0.002), and to 85(IQR 74-95;n=14;p=0.028) 12 months ast. Median total WHQ went from .32(IQR.23-.53) to .24(IQR.12-.39) after 12 weeks of treatment (p=0.000), and was .20(IQR.09-.27) 12 months ast (p=0.002). Positive effects on sleep, vasomotor symptoms and anxiety were most prominent. Eighteen women with HT had a baseline median number of flushes/24 h of 6.6(IQR:4.0-8.9), and 0.0(IQR:0.0-1.6; p=0.001) at 12 weeks. KI went from a median score of 23(IQR15-28;n=18) to 6(IQR3-9 ;n=18) after 12 weeks of treatment (p<0.001), and to 6(IQR2-8 ;n=17) at 12 months ast (p=0.001). Their median PGWB changed from 75(IQR59-88;n=18) at baseline to 90(IQR62-97;n=18) after 12 weeks of treatment (p=0.102), and to 93(IQR86-97;n=17;p=0.008) 12 months ast. Median total WHQ changed from .29(IQR.15-.44) to .15 (IQR.05-.22) (p=0.001) and was .09(IQR .06-,21; p=0.000) at 12 months ast. Number of times woken up/night went from 3.2(IQR1.1-5.6) in the EA group, to 2.2(IQR0-5;p=0.009)after 12 weeks of treatment, and was 1.6(IQR.4-3.3;p=0.003) at 12 months ast. In the HT group, times woken up/night at baseline was 2.1(IQR0-3.9), and after 12 weeks of treatment 1.2(IQR0-2;p=0.006). Discussion: EA is a possible treatment of vasomotor symptoms for women with breast cancer. Although the reduction of hot flushes is stronger with HT than EA, the increase in wellbeing is similar after EA as during HT. Acupuncture should be further studied for this group of women. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2162.